IQVIA's CEO Just Cashed $26.1 Million as Record $3.15 Billion Bookings Push the Stock to a 52-Week High

Record bookings improved the story, but the sale keeps this a watchlist setup

IQVIA's latest quarter made the bull case easier to see: R&D Solutions posted R&D Solutions Net New Bookings $3.15 billion, up 19% year-over-year, 1.22x book-to-bill ratio, and the stock rose 14.34% to $243.81 in premarket trading. At the same time, CEO Ari Bousbib sold about $26.09 million of stock on July 29, 2026, in shares traded from $244.60 to $247.18. The selling does not cancel out the operating improvement, but it does make the setup harder to chase blindly.

The positive case is straightforward. IQVIA reported Revenue $4,368 million, up 8.7% year-over-year and Adjusted Diluted Earnings per Share $3.15, up 12.1% year-over-year, while management pointed to stronger RFP flow and improving win rates on the earnings call. If that momentum continues, the stock still has a case for further gains.

The caution case is simpler: timing and alignment. Bousbib's sale came as the shares traded near its 52-week high of $251.36. Bulls can reasonably note that he still directly owns 835,941 shares and indirectly owns 543,302 shares through the Orohena Trust, so this was not a full exit. Still, a large sale near highs is enough to keep this on a watchlist rather than turning it into an obvious chase.

Why the market reacted: revenue, earnings, and bookings improved together

After the CEO's sale of common stock totaling approximately $26.09 million on July 29, 2026 and the 14.34% to $243.81 in premarket trading, the operating story is what matters most. Did IQVIA just get a one-day rerating, or did the business actually improve?

Guidance already moved higher before the premarket pop

Q2 hit the three metrics analysts watch first: Revenue $4,368 million, up 8.7% year-over-year, adjusted EPS of $3.15, and adjusted EBITDA of $994 million, up 9.2% year-over-year. Those results came after management had already started moving expectations higher.

In February, IQVIA guided to Full-year 2026 Revenue guidance of $17,150 million to $17,350 million, Adjusted EBITDA of $3,975 million to $4,025 million and Adjusted Diluted Earnings per Share of $12.55 to $12.85. By the first quarter, management had raised EPS guidance to $12.65 to $12.95. A strong second quarter does more than beat the quarter; it supports the case for another repricing of the full-year outlook.

R&D Solutions bookings kept improving quarter over quarter

The clearest operating signal came from order flow. In addition to the current quarter's R&D Solutions Net New Bookings $3.15 billion, up 19% year-over-year, 1.22x book-to-bill ratio, the segment had already posted R&D Solutions Net New Bookings of $2.5 billion in the first quarter. Looking back further, the fourth quarter of 2025 showed R&D Solutions quarterly bookings of over $2.7 billion, representing a book-to-bill ratio of 1.18x.

That sequence points to improving demand, not a one-off quarter. Bookings above 1.1x across multiple quarters suggest new business is arriving faster than revenue recognition, which is usually what investors want to see ahead of earnings acceleration.

Stronger results still leave less room for error

The bullish case is not just theory. IQVIA entered 2026 with a solid base, including R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year and Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year.

But once a stock is near a 52-week high and has already gapped up, improvement alone is not always enough. The market will now want proof that backlog can convert into revenue, earnings, and cash flow at an even faster pace.

• Bull watchpoint: Bookings remain above 1.1x and management raises full-year estimates again.
• Bear watchpoint: Backlog stays large, but revenue and cash-flow growth do not accelerate fast enough to justify chasing the stock after a big premarket jump.